Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akcea Therapeutics, Inc.    AKCA

AKCEA THERAPEUTICS, INC.

(AKCA)
  Report
SummaryQuotesChartsNewsRatingsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA

09/04/2020 | 07:50pm EST

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akcea Therapeutics, Inc. (NasdaqGS: AKCA) to Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS). Under the terms of the proposed transaction, shareholders of Akcea will receive only $18.15 in cash for each share of Akcea that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-akca/ to learn more.

Please note that the merger is structured as a tender offer, such that time may be of the essence.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.


© Business Wire 2020
All news about AKCEA THERAPEUTICS, INC.
11/10IONIS PHARMACEUTICALS : Akcea Therapeutics - WAYLIVRA, the first and only therap..
AQ
11/09IONIS PHARMACEUTICALS : and Akcea Recognize FCS Awareness Day with Global Commun..
AQ
11/04IONIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
11/04Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study ..
AQ
11/02IONIS PHARMACEUTICALS : and Akcea win prestigious Prix Galien Award for TEGSEDI ..
AQ
10/13IONIS PHARMACEUTICALS : completes acquisition of Akcea Therapeutics
AQ
10/13AKCEA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Notice of..
AQ
10/13IONIS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, ..
AQ
10/12AKCEA THERAPEUTICS : Ionis Pharmaceuticals completes acquisition of Akcea Therap..
PR
09/18AKCEA THERAPEUTICS : WAYLIVRA▼® (volanesorsen), the First and Only Therapy..
BU
More news
Financials (USD)
Sales 2019 489 M - -
Net income 2019 40,8 M - -
Net cash 2019 448 M - -
P/E ratio 2019 59,2x
Yield 2019 -
Capitalization 1 849 M 1 849 M -
EV / Sales 2018 37,6x
EV / Sales 2019 2,34x
Nbr of Employees 294
Free-Float 17,2%
Chart AKCEA THERAPEUTICS, INC.
Duration : Period :
Akcea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Damien McDevitt Chief Executive Officer
Brett P. Monia President & Director
Alex G. Howarth Chief Operating Officer
Michael Dennis Price Chief Financial Officer & Executive Vice President
William T. Andrews Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
AKCEA THERAPEUTICS, INC.7.26%1 849
JOHNSON & JOHNSON-1.28%379 086
ROCHE HOLDING AG-3.66%285 972
PFIZER INC.0.30%206 939
NOVARTIS AG-11.80%203 829
MERCK & CO., INC.-12.19%202 049